...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Problems in Cancer >Evaluation and management of the 'new' lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma.
【24h】

Evaluation and management of the 'new' lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma.

机译：评估和管理“新”淋巴瘤实体：套细胞淋巴瘤，粘膜相关淋巴样组织淋巴瘤，间变性大细胞淋巴瘤和原发性纵隔B细胞淋巴瘤。

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Non-Hodgkin's lymphomas (NHL) represent a major health problem worldwide, and incidence has been on the rise continuously for the last few decades. It is estimated that approximately 55,000 new cases of NHL will be diagnosed in the United States in 1998 and that slightly fewer than 25,000 patients will die of treatment failure or recurrent disease. The rising incidence of NHL is related not only to the acquired immunodeficiency syndrome epidemic but to also a steady increase in the number of cases diagnosed in older patients without immunosuppression. The new pathologic classification of NHL (revised European-American lymphoma classification, REAL) developed by the International Lymphoma Study Group (ILSG) is already resulting in more accurate disease-specific epidemiologic and clinical investigations. These studies have brought a new awareness of the existence and the relative prevalence of discrete NHL subtypes that appear to predominate among patients in different populations according to age, sex, geographic distribution, and predisposing conditions. This developing database has also the potential to result in the discovery of specific environmental causes, predisposing genetic factors, and therapeutic approaches. Some of the entities defined in the REAL classification, such as follicular lymphomas, diffuse B large-cell lymphomas, and T-cell lymphoblastic lymphomas, were already well described in the older classification systems (Kiel and Working Formulation). Others, such as mantle cell lymphoma, (MCL) anaplastic large-cell lymphoma (ALCL), lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), and primary mediastinal B-cell lymphoma (PMBCL) are relatively new members of the family, and accurate data on their clinicopathologic features and natural histories have only recently begun to emerge. This review presents in detail the most recent data on the clinical presentation of, diagnostic evaluation of, and treatment options for the most common of the new NHL entities: MCL, MALT lymphoma, CD30+ (Ki-1+) ALCL, and PMBCL. These four entities combined represent approximately 20% of all cases of NHL and exemplify well the broad clinicopathologic spectrum of NHL and the diagnostic and therapeutic challenges facing those who care for patients affected by these conditions.
机译：非霍奇金淋巴瘤（NHL）代表了世界范围内的主要健康问题，并且在过去的几十年中，发病率一直在不断上升。据估计，1998年在美国将诊断出约55,000例新的NHL病例，而略少于25,000例患者将死于治疗失败或复发性疾病。 NHL发病率的上升不仅与获得性免疫缺陷综合症的流行有关，而且与在没有免疫抑制的老年患者中诊断出的病例数稳定增加有关。国际淋巴瘤研究小组（ILSG）开发的新的NHL病理学分类（修订后的欧美淋巴瘤分类，REAL）已经导致更准确的针对疾病的流行病学和临床研究。这些研究使人们认识到离散NHL亚型的存在和相对患病率，根据年龄，性别，地理分布和易患病情况，这些亚型似乎在不同人群的患者中占主导地位。这个不断发展的数据库也有可能导致发现特定的环境原因，遗传因素和治疗方法。 REAL分类中定义的一些实体，例如滤泡性淋巴瘤，弥漫性B大细胞淋巴瘤和T细胞淋巴母细胞淋巴瘤，在较早的分类系统（Kiel和Working Formulation）中已经得到了很好的描述。其他，例如套细胞淋巴瘤（MCL），间变性大细胞淋巴瘤（ALCL），粘膜相关淋巴组织淋巴瘤（MALT淋巴瘤）和原发性纵隔B细胞淋巴瘤（PMBCL），是该家族的较新成员，关于其临床病理特征和自然历史的准确数据直到最近才开始出现。这篇综述详细介绍了最常见的新NHL实体：MCL，MALT淋巴瘤，CD30 +（Ki-1 +）ALCL和PMBCL的临床表现，诊断评估和治疗选择的最新数据。这四个实体合起来占所有NHL病例的大约20％，很好地体现了NHL的广泛临床病理学范围以及照顾那些受这些疾病影响的患者所面临的诊断和治疗挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号